Poly(ethylene glycol) (PEG, Mn = 35,000) was obtained from Merck (Darmstadt, Germany). α-Cyclodextrin (α-CD) was obtained from Ensuiko Sugar Refining (Tokyo, Japan). Sodium bromide (NaBr), sodium hypochlorite (NaClO; available chlorine less than 5%), 1H-benzotriazol-1yloxy)tris(dimethylamino)phosphorium hexafluorophosphate (BOP), and N,N-dimethylformamide (DMF) were obtained from Fujifilm Wako Pure Chemical Corporation (Osaka, Japan). 2,2,6,6-Tetramethylpiperidine 1-oxyl (TEMPO), 1-adamantylamine, and N,N-diisopropylethylamine (DIPEA) were obtained from Tokyo Chemical Industry (Tokyo, Japan). Other reagents and solvents were obtained from Kanto Chemical (Tokyo, Japan) and Fujifilm Wako Pure Chemical Corporation.
PEG-COOH (18.7 g, 93.3% yield). 1 H NMR (400 MHz, CDCl3) δ = 3.62 (m, -O-CH 2 -CH 2 -of PEG axle), 4.13 (s, -OCH 2 -C(=O)-).
S3. Synthesis of adamantyl group-capped polyrotaxanes (PRXs)
PRXs composed of α-CD as a cyclic molecule, PEG as an axle polymer, and adamantyl groups as stopper molecules were synthesized according to a previous study ( Figure S1 ) [1] . PEG-COOH (2.5 g, 714 μmol) and α-CDs (5 g, 5.14 mmol) were dissolved in distilled water (24.5 mL) and the mixture was stirred for 24 h at room temperature. The precipitate was collected by centrifugation (8,500 rpm, 3 min) and freeze-dried to obtain a pseudopolyrotaxane (6.02 g). Subsequently, 1-adamantylamine (389 mg, 2.57 mmol), BOP (1.14 g, 2.57 mμmol), and DIPEA (512 μL, 3 m mol) were dissolved in DMF (50.2 mL), and the solution was combined with pseudopolyrotaxane. The mixture was stirred for 24 h at room temperature. After the reaction, the precipitate was collected by centrifugation (8,500 rpm, 3 min), dissolved in a small aliquot of dimethyl sulfoxide (DMSO), reprecipitated in distilled water, and collected by centrifugation (8,500 rpm, 3 min). The reprecipitation process was repeated four times to completely remove the free α-CD and unreacted reagents. The recovered precipitate was freeze-dried to obtain PRX (2.96 g, 32.1% yield based on recovered PEG mol%). The number of threading α-CDs in the PRX was determined from the 1 H NMR spectrum. 1 PRXs were also characterized by size-exclusion chromatography (SEC) measurements using a Prominence-i LC-2030 Plus system (Shimadzu, Kyoto, Japan) equipped with an RID-20A refractive index detector (Shimadzu) and a combination of TSKgel α-4000 and α-2500 columns (300 mm length, 7.8 mm internal diameter) (Tosoh, Tokyo, Japan) ( Figure S2 ). Sample solutions were injected into the system and were eluted with DMSO containing 10 mM LiBr at a flow rate of 0.35 mL/min at 60 °C.
S4. Preparation of gelatin hydrogels with different amounts of CME-PRX-37% and EDC/NHS.
To verify the optimal conditions for preparing the gelatin hydrogels cross-linked by CME-PRXs, gelatin hydrogels with different amounts of CME-PRX-37% and EDC/NHS were prepared. In brief, the gelatin powder (100 mg) was dissolved in 0.1 M 2-(N-morpholino)ethanesulfonic acid (MES) buffer (1.0 mL) at 40 °C. CME-PRXs, EDC, and NHS were dissolved in 0.1 M MES buffer (1.0 mL) and activated for 10 min at room temperature. Activated CME-PRX solutions were then placed in the gelatin solution at a 1:1 volume ratio and stirred for 1 min at 40 °C. The gelatin hydrogels were then maintained at 37 °C to confirm the formation of the gelatin hydrogels cross-linked by CME-PRX-37%.
Stable hydrogels were obtained at optimal CME-PRX-37%:EDC:NHS ratios. In addition, the stretchability and toughness of the gelatin hydrogels cross-linked by CME-PRX-37% were optimal when the hydrogels were prepared at a CME-PRX-37% concentration of 1 mg/mL. By contrast, the stretchability and toughness of the gelatin hydrogels prepared at other CME-PRX-37% concentrations were low, which was probably due to excessive or ineffective cross-linking. 37%  Table S1 . Characterization of gelatin hydrogels with different concentration of CME-PRX-37% crosslinkers and amounts of EDC/NHS. Elongation at break (%) 0.5 mg/mL CME-PRX-37% 1 mg/mL CME-PRX-37% 6.35 mg/mL CME-PRX-37% Tensile strength (kPa) 0.5 mg/mL CME-PRX-37% 1 mg/mL CME-PRX-37% 6.35 mg/mL CME-PRX-37% 
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